The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?

The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?

After menopause, estradiol is primarily synthesized in peripheral tissues by the enzyme aromatase, encoded by CYP19A1. CYP19A1 variation associates with circulating estradiol in postmenopausal women and this variation is best represented by the intronic variant rs727479. This variation appears to ha...

Full description

Bibliographic Details
Main Authors: Dylan M. Glubb, Tracy A. O'Mara, Jannah Shamsani, Amanda B. Spurdle
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-04-01
Series:Frontiers in Pharmacology
Subjects:
CYP19A1
estradiol
genetic variation
aromatase inhibitors
patient outcome
breast cancer
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00218/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00218/full

Similar Items